SeaStar Medical (ICU) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$1.7M

Revenue (quarter)

$615,000.00

Revenue growth (year over year)

+81.95%

Gross profit (trailing twelve months)

$1.6M

Gross margin

92.64%

Net income (trailing twelve months)

−$13.6M

Net income (quarter)

−$3.7M

Net income growth (year over year)

−86.31%

Net margin

−795.50%

Return on equity

−356.87%

EPS (trailing twelve months)

−$1.89

Book value per share

$1.01

P/E (trailing twelve months)

—

Price to book

3.68

Debt to assets

50.33%

Payout ratio

—

Dividend yield

—

Company profile

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

• Is SeaStar Medical (ICU) profitable?

  No. SeaStar Medical reported a net loss of $13.6M over the trailing twelve months.

• How much revenue does SeaStar Medical (ICU) make?

  SeaStar Medical generated $1.7M in revenue over the trailing twelve months, up 81.95% year over year.

• How do I buy stock in SeaStar Medical (ICU)?

  ICU trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.